Gross won the Nobel Prize in Physics in 2004 for his discovery of asymptotic freedom in the theory of strong interactions. Recently, he received the $3 million Special Breakthrough Prize in Fundamental Physics. Asymptotic freedom describes how the force between quarks weakens as they come closer together.

Yet, Gross believes that humanity faces dire challenges ahead. He estimates a 2% chance of nuclear war each year. This leads to an expected lifetime for humanity of about 35 years. “The expected lifetime is about 35 years,” he stated plainly.

The risk of nuclear conflict has increased in recent years, according to Gross. There are currently nine nuclear powers in the world. This complicates global relations and escalates tensions.

“The chances of you living 50 years are very small,” Gross remarked. His assessment reflects growing concerns among scientists about geopolitical instability and military advancements.

Gross emphasizes that we are entering an incredible arms race. The dynamics of international politics and military strategy continue to evolve rapidly. Observers note that these developments could have lasting implications for global security.

His work has contributed significantly to the unification of fundamental forces in physics—completing what is known as the Standard Model of particle physics. However, despite these scientific advancements, the looming threat of nuclear war overshadows progress.

Details remain unconfirmed regarding future measures to mitigate these risks. The scientific community watches closely as experts debate solutions to avert potential disaster.

The post David Gross Physics: A Nobel Laureate’s Warning for Humanity appeared first on newscri.

The American Heart Association (AHA) and the American College of Cardiology (ACC) have announced the 2026 cholesterol guidelines, marking a significant update in the approach to cholesterol management. These guidelines emphasize the importance of early detection and personalized treatment strategies to prevent heart disease.

According to the new guidelines, cholesterol checks should begin at age 19, with repeat testing every five years. This early intervention aims to identify individuals at risk and implement preventive measures sooner.

One of the notable introductions in the 2026 guidelines is a new risk assessment tool called PREVENT. This tool allows healthcare providers to estimate cardiovascular risk over 10 and 30 years, facilitating more tailored treatment plans for patients.

The guidelines also highlight that lipid-lowering therapy can now be considered for primary prevention in borderline-risk patients, defined as having a 3-5% percentage risk. For those at intermediate risk, the percentage rises to 5-10%.

For adults aged 40 to 75 years with diabetes or chronic renal disease, the guidelines recommend LDL-lowering therapy regardless of LDL-C levels. This shift underscores the growing recognition of the need for proactive management in these high-risk groups.

Furthermore, the LDL-C target for secondary prevention is suggested to be less than 55 mg/dL for high-risk patients, reinforcing the focus on aggressive treatment strategies.

Statins continue to be recognized as the first-line treatment for patients with dyslipidemia, with the guidelines stating, “Statins remain the cornerstone of therapy; multiple add-on options available.” Additionally, apolipoprotein B (ApoB) testing is recommended, particularly for patients with high triglycerides or diabetes.

At least one lifetime measurement of lipoprotein(a) is advised for all adults, and coronary artery calcium (CAC) scoring is indicated for borderline or intermediate-risk individuals, further enhancing the comprehensive approach to dyslipidemia care.

The 2026 guidelines supersede the previous 2018 AHA/ACC cholesterol guidelines and reflect the latest findings from clinical trials. As healthcare professionals begin to implement these recommendations, the focus will be on improving patient outcomes through early intervention and personalized care.

Initial reactions to the guidelines have been positive, with experts noting that prevention starts early in life. The emphasis on comprehensive dyslipidemia care marks a significant shift in how cholesterol management is approached.

The post AHA ACC Cholesterol Guidelines 2026 appeared first on newscri.